Important regulatory notice. No peptide sold as a research-use-only reference compound is licensed by the MHRA as a treatment for IBS or other gastrointestinal disease in the United Kingdom. This page is a literature-context overview of compound families discussed in published gastrointestinal research. It is not personal-use guidance. Peptides Lab UK supplies research-use-only laboratory reference compounds. Products are not for human or veterinary use.
Quick research summary. The published gastrointestinal research literature spans intestinal barrier biology, the enteric nervous system, mucosal immunity, microbiome biology and gastrointestinal motility. Several peptide families appear in this research record. None is a licensed UK IBS or gut-health treatment in the research-use-only category.
Gut biology context
Gastrointestinal literature covers the intestinal epithelial barrier (tight-junction biology, paracellular permeability), the enteric nervous system (the ‘second brain’), mucosal immunity (gut-associated lymphoid tissue), the microbiome and microbiota-host crosstalk, gastrointestinal motility (the migrating motor complex and serotonergic signalling), and the brain-gut axis. Each axis has its own substantial peer-reviewed literature.
Compound families that appear in the published research record
Cell-culture, organoid and rodent-model gut research has discussed several peptide families. BPC-157 appears in gastrointestinal mucosal injury models. Glucagon-like peptide-2 (GLP-2) research peptides appear in intestinal trophic biology research. Antimicrobial peptide research is relevant to host-defence and microbiome biology. None of these is a research-use-only product on this site that should be understood as a treatment.
Where licensed UK gastrointestinal treatments fit
UK IBS and gut-health treatment is delivered through NHS gastroenterology services using a range of MHRA-licensed approaches including dietary intervention (low-FODMAP, dietitian referral), antispasmodics, probiotics in defined contexts, and other licensed therapies. Teduglutide (a GLP-2 analogue) is licensed in defined short-bowel-syndrome indications. None of these are research-use-only peptide reference compounds.
UK regulatory position
No research-use-only peptide on this site is a licensed treatment for IBS or gut health. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products.
For laboratory researchers
Gastrointestinal researchers may use peptide reference compounds in in-vitro, organoid and animal-model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.
If you have IBS or other gut symptoms
The standard NHS pathway is via your GP. The IBS Network (theibsnetwork.org) and Guts UK (gutscharity.org.uk) are useful UK resources.
Research use only. Peptides Lab UK supplies research-use-only laboratory reference compounds with batch-specific certificates of analysis. Products are not for human or veterinary use.
